Radiolabeled Monoclonal Antibody Imaging of Tumors and Positron Emission Tomograp

肿瘤放射性标记单克隆抗体成像和正电子发射断层扫描

• 批准号: 6103612
• 负责人: JORGE A. CARRASQUILLO
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6103612
• 关键词: antitumor antibody; athymic mouse; clinical research; clinical trial phase I; human subject; immunoglobulin G; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide diagnosis; neoplasm /cancer radionuclide therapy; neoplasm /cancer transplantation; nuclear medicine; radiation therapy dosage; radionuclide imaging /scanning; radiopharmacology; xenotransplantation; yttrium

These studies are designed to develop improved methods for detecting and treating malignancies. Our group performs preclinical evaluation of antibodies that appear to be promising after initial screening by various laboratories at the National Cancer Institute and develops these antibodies for clinical staff. They are then administered to patients under the supervision of a nuclear medicine physician and an assistant in the Nuclear Medicine Department. Serial blood samples, urine specimens, and often bone marrow or tumor biopsies are obtained to evaluate the distribution of the monoclonal antibody in the body.We have completed all of the phase I trial with B3, in collaboration with Dr. Ira Pastan. A total of 26 patients were accrued.Our collaborative radioimmunotherapy trial with Dr. Waldmann (PI) in which we used humanized anti-tac monoclonal antibody, is ongoing. We have accrued 18 patients with ATL or with non ATL T-cell lymphoma.Imaging studies comparing the use of Tc-99m anti-CEA Fab (FDA approved) and F-18 deoxyglucose have been started in patients with previous history of colorectal carcinoma and rising CEA without evidence of disease by conventional radiographic modalities. We have studied 12 patients to date.We have completed preclinical studies with radiolabeled immunotoxin developed by Dr. Pastan's Laboratory.From the four stereosiomers of CHX-DTPA we have selected CHX-A1, the most stable for Y-90 chelation, as our preferred chelate for antibody trials.

这些研究旨在开发改进的 检测和治疗恶性肿瘤的方法。我们集团 进行抗体的临床前评价， 经过各实验室的初步筛选， 国家癌症研究所和开发这些抗体的临床 工作人员然后在医生的监督下， 一位核医学医生和一位核医学助理 医药部。连续的血液样本，尿液样本，和 通常获得骨髓或肿瘤活组织检查以评估 单克隆抗体在体内的分布。我们有 完成了所有的第一阶段试验与B3，在合作博士。 伊拉帕斯坦。共有26名患者参加。我们的合作 Waldmann博士（PI）的放射免疫治疗试验， 使用人源化抗tac单克隆抗体，正在进行中。我们有 收集了18例ATL或非ATL T细胞 比较使用Tc-99m抗CEA的影像学研究 Fab（FDA批准）和F-18脱氧葡萄糖已于 既往有结直肠癌病史且 常规放射学检查无疾病证据的CEA 方式。到目前为止，我们已经研究了12名患者。 放射性标记免疫毒素的临床前研究， 从CHX-DTPA的四种立体异构体 我们选择了CHX-A1，它对Y-90螯合作用最稳定， 我们在抗体试验中的首选螯合物